外周T细胞淋巴瘤治疗进展课题.ppt

结 语 CHOP/CHOP样方案尽管疗效欠佳，目前仍为一线方案 有多种新药应用于PTCL治疗中 分子靶向新药联合CHOP方案可能是将来发展方向 首次缓解后推荐行自体造血干细胞移植，能够提高5年PFS和OS，高选择性病例可以考虑异基因移植，但是缺少大组病例的随机研究 难治复发患者推荐进行临床试验 谢 谢 ！ Epratuzumab+RCHOP Blood 2012 Jan * * [slide 4] Epidemiology of CML Globally, CML has an incidence of 1 to 2 cases per 100,000 population and is responsible for 15% to 20% of all adult leukaemia. The median age at presentation is 53, with a median range of 45 to 55 years.1 The incidence of CML increases with age; up to 30% of patients are 60 years of age or older at presentation, which may influence the selection of tr